Abstract: Systems and methods for aromatic macrocyclic compounds (Phthalocyanines) as cathode additives for inhibition of transition metal dissolution and stable solid electrolyte interphase formation may include an anode, an electrolyte, and a cathode, where the cathode comprises an active material and a phthalocyanine additive, the additive being coordinated with different metal cationic center and functional groups. The active material may comprise one or more of: nickel cobalt aluminum oxide, nickel cobalt manganese oxide, lithium iron phosphate, lithium cobalt oxide, and lithium manganese oxide, Ni-rich layered oxides LiNi1-xMxO2 where M=Co, Mn, or Al, Li-rich xLi2MnO3(1-x)LiNiaCobMncO2, Li-rich layered oxides LiNi1+xM1?xO2 where M=Co, Mn, or Ni, and spinel oxides LiNi0.5Mn1.5O4.

Abstract: A method for formation of cylindrical and prismatic can cells may include providing a battery, where the battery includes one or more cells, with each cell including at least one silicon-dominant anode, a cathode, and a separator. The battery also includes a metal can that contains the one or more cells such that during formation a pressure between 50 kPa and 1 MPa is applied to the one or more cells. The battery may include strain absorbing materials arranged between the one or more cells and interior walls of the can. The strain absorbing materials may include foam. The strain absorbing materials may include a solid electrolyte layer. The strain absorbing materials may include PMMA, PVDF, or a combination thereof. The pressure during a formation process may be due to a thickness of the strain absorbing materials being thicker than an expansion of the one or more cells.

Abstract: VHH domains that bind to p1gR are described. The VHH domain may compete with IgA binding to p1gR, or alternatively, the VHH domain may compete with IgA binding to p1gR. The VHH domains may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via p1gR-mediated transcytosis. The therapeutic agent can be a small molecule, large molecule, or even an antibody.

Abstract: A method, controller, and non-transitory computer-readable medium of a distributed crypto-ledger network, including receiving an instruction to perform an operation between a first user and a second user, the first user corresponding to a first entity that is a member of the distributed crypto-ledger network, the instruction comprising a destination address corresponding to the second user, querying a top-level name registry with the destination address to determine a second entity associated with the destination address, the second entity being a different member of the crypto-ledger network, and executing the operation between the first user and the second user by transmitting execution instructions to the first entity and the second entity, the execution instructions causing a first entity controller to modify data stored on a first distributed crypto-ledger of the first entity, and causing a second entity controller to modify data stored on the second distributed crypto-ledger of the second entity.

Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3?, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Abstract: Systems and methods utilizing water soluble (aqueous) PAA-based polymer binders for silicon-dominant anodes may include an electrode coating layer on a current collector, where the electrode coating layer is formed from silicon and a pyrolyzed water soluble PAA-based polymer blend, wherein the water soluble PAA-based polymer blend comprises PAA and one or more additional water-soluble polymer components. The electrode coating layer may include more than 70% silicon and the anode may be in a lithium ion battery.

Abstract: Systems and methods are provided for configuring cell performance using specific anode, cathode, and separator combinations. Separators with significant adhesive properties may be used in forming rechargeable cells, such as lithium-ion cells. The separator with significant adhesive properties may include an adhesive coating, applied on one or both sides of the separator, and/or adhesive material is dissolved or deposited within the separator. The separators with significant adhesive properties may also include one or more ceramic layers.

Abstract: A method and system for carbon-coated silicon in a pyrolyzed carbon binder electrode on copper current collectors may include providing a metal current collector; forming a non-porous carbon coating on the metal current collector; coating silicon particles with carbon; forming an active material layer on the metal current collector, where the active material layer comprises at least 50% silicon particles by weight and a carbon source; and pyrolyzing the active material layer on the metal current collector, with no silicon particles in contact with metal from the metal current collector. The metal current collector may include copper. The battery anode may include no copper-silicon eutectic. The silicon particles may range in size from 2 to 50 ?m. The active material layer may include aluminum carbide. A source for the pyrolyzed carbon may include polyimide and/or polyamide-imide. The current collector may be coated with the non-porous carbon coating using physical vapor deposition.

Abstract: A population of antibodies, wherein less than 80% of the oligosaccharides covalently attached to the population of the antibodies via N297 residues thereof comprise a core fucose residue; and wherein the population of the antibodies comprises an antibody which Fc region comprises K338A and T437R mutations, or K248E and T437R mutations.

Abstract: Systems and/or methods of the present disclosure enable crypto-ledger interoperability using a controller to perform an operation between a first user and a second user on separate entity-specific distributed crypto-ledgers, where the separate entity-specific distributed crypto-ledgers are both operatively linked to a membered common distributed crypto-ledger. The controller burns a first quantity of first entity-specific crypto-tokens from the first entity-specific distributed crypto-ledger and mints a second quantity of the common crypto-tokens on the membered common distributed crypto-ledger, where the first quantity of first entity-specific crypto-tokens and the second quantity of the common crypto-tokens represent an equivalency.

Abstract: A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.

Abstract: Provided herein are multispecific antibodies, including trispecific antibodies that bind to CD79b, CD20 and CD3, and bispecific antibodies that bind to CD79b and CD3, and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are isolated antibodies that bind to CD79b and antigen-binding fragments thereof.

Abstract: Provided herein are chimeric antigen receptors (CARs), cells comprising the CARs, monoclonal and bispecific antibodies or antigen-binding fragments thereof, and kits comprising the same. The CARs and bispecific antibodies are designed to target at least one tumor antigen and at least one tumor in methods of treating cancer in subjects in need thereof.

Abstract: Provided herein are multispecific antibodies, that bind to CD79b and CD22, polynucleotides encoding them, vectors, host cells, methods of making and using them.

Abstract: Anti-TRGV9 molecules, such as anti-TRGV9 antibodies or antigen binding fragments thereof, are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

Abstract: Systems and methods for aromatic macrocyclic compounds (Phthalocyanines) as cathode additives for inhibition of transition metal dissolution and stable solid electrolyte interphase formation may include an anode, an electrolyte, and a cathode, where the cathode comprises an active material and a phthalocyanine additive, the additive being coordinated with different metal cationic center and functional groups. The active material may comprise one or more of: nickel cobalt aluminum oxide, nickel cobalt manganese oxide, lithium iron phosphate, lithium cobalt oxide, and lithium manganese oxide, Ni-rich layered oxides LiNi1?xMxO2 where M=Co, Mn, or Al, Li-rich xLi2MnO3(1?x)LiNiaCobMncO2, Li-rich layered oxides LiNi1+xM1?O2 where M=Co, Mn, or Ni, and spinel oxides LiNi0.5Mn1.5O4.

Abstract: The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis.

Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.

Abstract: A molecule comprising a first means of binding to a first antigen expressed on a regulatory T (Treg) cell, and a second means capable of binding to a second antigen expressed on the Treg cell, wherein the molecule is capable of inhibiting growth or proliferation of or depleting a Treg cell.

Abstract: Provided herein are multispecific antibodies that bind to BCMA, GPRC5D and CD3 and multispecific antigen-binding fragments thereof. Also described are related polynucleotides capable of encoding the provided multispecific antibodies or multispecific antigen-binding fragments, cells expressing the provided multispecific antibodies or multispecific antigen-binding fragments, as well as associated vectors and detectably labeled multispecific antibodies or multispecific antigen-binding fragments. In addition, methods of producing and using the provided multispecific antibodies and multispecific antigen-binding fragments are described. Further provided herein are antibodies that bind to BCMA and antigen-binding fragments thereof.